- Home
- YCBD vs HCWB Comparison
YCBD vs HCWB Comparison
Compare YCBD & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | HCWB |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.0M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YCBD | HCWB |
|---|---|---|
| Price | $0.48 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $35.00 |
| AVG Volume (30 Days) | 142.3K | ★ 163.1K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,190,468.00 | $4,099,750.00 |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.25 |
| 52 Week High | $2.56 | $6.11 |
Technical Indicators
Market Signals| Indicator | YCBD | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 41.36 |
| Support Level | $0.47 | $2.35 |
| Resistance Level | $0.53 | $4.01 |
| Average True Range (ATR) | 0.03 | 0.38 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 36.22 | 21.59 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.